DNLI
Price
$14.69
Change
-$0.21 (-1.41%)
Updated
Jul 3 closing price
Capitalization
2.13B
25 days until earnings call
VRDN
Price
$15.67
Change
+$0.44 (+2.89%)
Updated
Jul 3 closing price
Capitalization
1.28B
30 days until earnings call
Interact to see
Advertisement

DNLI vs VRDN

Header iconDNLI vs VRDN Comparison
Open Charts DNLI vs VRDNBanner chart's image
Denali Therapeutics
Price$14.69
Change-$0.21 (-1.41%)
Volume$613.31K
Capitalization2.13B
Viridian Therapeutics
Price$15.67
Change+$0.44 (+2.89%)
Volume$396.66K
Capitalization1.28B
DNLI vs VRDN Comparison Chart in %
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. VRDN commentary
Jul 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Hold and VRDN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 07, 2025
Stock price -- (DNLI: $14.69 vs. VRDN: $15.67)
Brand notoriety: DNLI and VRDN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 41% vs. VRDN: 52%
Market capitalization -- DNLI: $2.13B vs. VRDN: $1.28B
DNLI [@Biotechnology] is valued at $2.13B. VRDN’s [@Biotechnology] market capitalization is $1.28B. The market cap for tickers in the [@Biotechnology] industry ranges from $316.35B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileVRDN’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • VRDN’s FA Score: 0 green, 5 red.
According to our system of comparison, VRDN is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 4 TA indicator(s) are bullish while VRDN’s TA Score has 5 bullish TA indicator(s).

  • DNLI’s TA Score: 4 bullish, 5 bearish.
  • VRDN’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, VRDN is a better buy in the short-term than DNLI.

Price Growth

DNLI (@Biotechnology) experienced а +1.38% price change this week, while VRDN (@Biotechnology) price change was +7.70% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.30%. For the same industry, the average monthly price growth was +17.40%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

DNLI is expected to report earnings on Jul 31, 2025.

VRDN is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+6.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($2.13B) has a higher market cap than VRDN($1.28B). VRDN YTD gains are higher at: -18.258 vs. DNLI (-27.920). VRDN has higher annual earnings (EBITDA): -304.76M vs. DNLI (-505.16M). DNLI has more cash in the bank: 818M vs. VRDN (637M). VRDN has less debt than DNLI: VRDN (21.2M) vs DNLI (48.6M). VRDN has higher revenues than DNLI: VRDN (302K) vs DNLI (0).
DNLIVRDNDNLI / VRDN
Capitalization2.13B1.28B167%
EBITDA-505.16M-304.76M166%
Gain YTD-27.920-18.258153%
P/E RatioN/AN/A-
Revenue0302K-
Total Cash818M637M128%
Total Debt48.6M21.2M229%
FUNDAMENTALS RATINGS
DNLI vs VRDN: Fundamental Ratings
DNLI
VRDN
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
92
Overvalued
PROFIT vs RISK RATING
1..100
10088
SMR RATING
1..100
9498
PRICE GROWTH RATING
1..100
6048
P/E GROWTH RATING
1..100
99100
SEASONALITY SCORE
1..100
n/a29

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VRDN's Valuation (92) in the Biotechnology industry is in the same range as DNLI (93). This means that VRDN’s stock grew similarly to DNLI’s over the last 12 months.

VRDN's Profit vs Risk Rating (88) in the Biotechnology industry is in the same range as DNLI (100). This means that VRDN’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (94) in the Biotechnology industry is in the same range as VRDN (98). This means that DNLI’s stock grew similarly to VRDN’s over the last 12 months.

VRDN's Price Growth Rating (48) in the Biotechnology industry is in the same range as DNLI (60). This means that VRDN’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's P/E Growth Rating (99) in the Biotechnology industry is in the same range as VRDN (100). This means that DNLI’s stock grew similarly to VRDN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLIVRDN
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
81%
Bullish Trend 4 days ago
75%
Momentum
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
74%
MACD
ODDS (%)
Bullish Trend 4 days ago
78%
Bearish Trend 4 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 4 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
75%
Bullish Trend 4 days ago
80%
Advances
ODDS (%)
Bullish Trend 11 days ago
78%
Bullish Trend 4 days ago
79%
Declines
ODDS (%)
Bearish Trend 7 days ago
80%
Bearish Trend 7 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
73%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
79%
Bullish Trend 4 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FBMPX126.350.92
+0.73%
Fidelity Select Communication Services
LISGX68.650.49
+0.72%
ClearBridge Small Cap IS
BWLYX24.520.16
+0.66%
American Beacon Man Lg Cp Value Y
TEGRX29.540.13
+0.44%
Templeton Growth R
LYFIX12.32-0.01
-0.08%
AlphaCentric Life Sciences & Hlthcare I

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with BEAM. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-1.41%
BEAM - DNLI
62%
Loosely correlated
+0.65%
NRIX - DNLI
59%
Loosely correlated
+2.33%
RGNX - DNLI
58%
Loosely correlated
+1.39%
ARWR - DNLI
58%
Loosely correlated
-0.65%
ATXS - DNLI
57%
Loosely correlated
+1.40%
More

VRDN and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRDN has been loosely correlated with AURA. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if VRDN jumps, then AURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRDN
1D Price
Change %
VRDN100%
+2.89%
AURA - VRDN
52%
Loosely correlated
+1.55%
DNLI - VRDN
51%
Loosely correlated
-1.41%
DSGN - VRDN
49%
Loosely correlated
+2.45%
BEAM - VRDN
47%
Loosely correlated
+0.65%
OCUL - VRDN
47%
Loosely correlated
+1.69%
More